Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2015

01-04-2015 | Original Article

Comparison of diameter-axial-polar nephrometry and RENAL nephrometry score for treatment decision-making in patients with small renal mass

Authors: Yoshio Naya, Akihiro Kawauchi, Masakatu Oishi, Takashi Ueda, Atsuko Fujihara, Yasuyuki Naito, Terukazu Nakamura, Fumiya Hongo, Kazumi Kamoi, Koji Okihara, Tsuneharu Miki

Published in: International Journal of Clinical Oncology | Issue 2/2015

Login to get access

Abstract

Introduction

The aim of this study was to evaluate our institution’s experience in performing laparoscopic radical nephrectomy (LRN) and partial nephrectomy (PN) in patients with small renal masses.

Methods

142 patients with cT1aN0M0 lesions were identified. 68 of these subjects were treated with LRN and 74 were treated with laparoscopic PN (LPN). The clinicopathological characteristics of the two groups of patients, including diameter-axial-polar (DAP) nephrometry and RENAL nephrometry score (RENAL-NS), operative results, and outcomes, were retrospectively analyzed.

Results

A multivariate logistic regression analysis for the selection of PN as the treatment showed that tumor size, DAP nephrometry, RENAL-NS and imperative condition were all independent factors. The area under the curve receiver operating characteristics (ROC-AUC) of DAP and RENAL-NS for performing LPN were 0.897 and 0.825, respectively.

Conclusions

Although LRN was performed in patients with a high nephrometry score in this study, open partial nephrectomy (OPN) should be considered for patients with a high nephrometry score in T1a renal cell carcinoma (RCC) because of better functional and similar oncological outcomes. Based on ROC analysis, when DAP is 6 or less, LPN should be considered and when DAP is 7 or more, OPN should be considered.
Literature
1.
go back to reference Heuer R, Gill IS, Guazzoni G et al (2010) A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 57:223–232CrossRefPubMed Heuer R, Gill IS, Guazzoni G et al (2010) A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 57:223–232CrossRefPubMed
2.
go back to reference Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma––a meta analysis and review. J Urol 179:1227–1233CrossRefPubMed Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma––a meta analysis and review. J Urol 179:1227–1233CrossRefPubMed
3.
go back to reference Huang WC, Elkin EB, Levey AS et al (2009) Partial nephrectomy versus radical nephrectomy in patients with small renal tumors––is there a difference in mortality and cardiovascular outcomes? J Urol 181:55–61 (discussion 62)CrossRefPubMedCentralPubMed Huang WC, Elkin EB, Levey AS et al (2009) Partial nephrectomy versus radical nephrectomy in patients with small renal tumors––is there a difference in mortality and cardiovascular outcomes? J Urol 181:55–61 (discussion 62)CrossRefPubMedCentralPubMed
4.
go back to reference Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumors: a retrospective cohort study. Lancet Oncol 7:735–740CrossRefPubMedCentralPubMed Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumors: a retrospective cohort study. Lancet Oncol 7:735–740CrossRefPubMedCentralPubMed
5.
go back to reference European Association of Urology (2014) EAU Guidelines on Renal Cell Carcinoma: The 2014 Update European Association of Urology (2014) EAU Guidelines on Renal Cell Carcinoma: The 2014 Update
6.
go back to reference National Comprehensive Cancer Network (2014) NCCN Guidelines™ Version 2. 2014 Kidney Cancer National Comprehensive Cancer Network (2014) NCCN Guidelines™ Version 2. 2014 Kidney Cancer
7.
go back to reference Marszalek M, Meixl H, Polajnar M et al (2009) Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. Eur Urol 55:1171–1178CrossRefPubMed Marszalek M, Meixl H, Polajnar M et al (2009) Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. Eur Urol 55:1171–1178CrossRefPubMed
8.
go back to reference Kutikov A, Uzzo RG (2009) The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182:844–853CrossRefPubMed Kutikov A, Uzzo RG (2009) The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182:844–853CrossRefPubMed
9.
go back to reference Simmons MN, Hillyer SP, Lee BH et al (2012) Diameter-axial-polar nephrometry: integration and optimization of RENAL and centrality index scoring systems. J Urol 188:384–390CrossRefPubMed Simmons MN, Hillyer SP, Lee BH et al (2012) Diameter-axial-polar nephrometry: integration and optimization of RENAL and centrality index scoring systems. J Urol 188:384–390CrossRefPubMed
10.
go back to reference Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
11.
go back to reference Japanese Society of Nephrology (2009) Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol 13:537–566 Japanese Society of Nephrology (2009) Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol 13:537–566
12.
go back to reference Lai FC, Kau EL, Ng CS et al (2007) Laparoscopic nephrectomy outcomes of elderly patients in the 21st century. J Endourol 21:1309–1313CrossRefPubMed Lai FC, Kau EL, Ng CS et al (2007) Laparoscopic nephrectomy outcomes of elderly patients in the 21st century. J Endourol 21:1309–1313CrossRefPubMed
13.
go back to reference Berger A, Crouzet S, Canes D et al (2008) Minimally invasive nephron-sparing surgery. Curr Opin Urol 18:462–466CrossRefPubMed Berger A, Crouzet S, Canes D et al (2008) Minimally invasive nephron-sparing surgery. Curr Opin Urol 18:462–466CrossRefPubMed
14.
go back to reference Broughton GJ, Clark P, Barocas DA et al (2012) Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. BJU Int 109:1607–1613CrossRefPubMed Broughton GJ, Clark P, Barocas DA et al (2012) Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. BJU Int 109:1607–1613CrossRefPubMed
15.
go back to reference Zini L, Perrotte P, Capitanio U et al (2009) Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 115:1465–1471CrossRefPubMed Zini L, Perrotte P, Capitanio U et al (2009) Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 115:1465–1471CrossRefPubMed
Metadata
Title
Comparison of diameter-axial-polar nephrometry and RENAL nephrometry score for treatment decision-making in patients with small renal mass
Authors
Yoshio Naya
Akihiro Kawauchi
Masakatu Oishi
Takashi Ueda
Atsuko Fujihara
Yasuyuki Naito
Terukazu Nakamura
Fumiya Hongo
Kazumi Kamoi
Koji Okihara
Tsuneharu Miki
Publication date
01-04-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-014-0714-2

Other articles of this Issue 2/2015

International Journal of Clinical Oncology 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine